|
1) Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-hepatic adult stem cells. Nature. 2000; 406: 257
|
|
|
|
2) Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology. 2000; 32: 11-6
|
|
|
|
|
|
3) Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology. 2008; 135: 438-50
|
|
|
|
|
|
4) Terai S, Sakaida I, Yamamoto N, et al. An in vivo model for minitoring the transdifferentiation of bone marrow cells into functinal hepatocytes. J Biochem. 2003; 134: 551-8
|
|
|
|
|
5) Terai S, Sakaida I, Nishina H, et al. Lesson from the GFP/CCl4 model-translational research project: the development of cell therapy using autologous bone marrow cells in patients with liver cirrhosis. J Hepatobiliary Pancreat Surg. 2005; 12: 203-7
|
|
|
|
|
|
6) Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004; 40: 1304-11
|
|
|
|
|
|
7) Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006; 24: 2292-8
|
|
|
|
|
|
8) Gordon MY, Levicar N, Pai M, et al. Characterization and clinical application of human CD34＋ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006; 24: 1822-30
|
|
|
|
|
|
9) Levicar N, Pai M, Habib NA, et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34＋ cells in patients with chronic liver disease. Cell Prolif. 2008; 41 Suppl 1: 115-25
|
|
|
|
|
|
10) am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133＋ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005; 23: 463-70
|
|
|
|
|
|
11) Fürst G, Schulte am Esch J, Poll LW, et al. Portal vein embolization and autologous CD133＋ bone marrow stem cells for liver regeneration: initial experience. Radiology. 2007; 243: 171-9
|
|
|
|
|
|
12) Yamamoto N, Terai S, Ohata S, et al. A subpopulation of bone marrow cells depleted by a novel antibody, anti-Liv8, is useful for cell therapy to repair damaged liver. Biochem Biophys Res Commun. 2004; 313: 1110-8
|
|
|
|
|
|
13) Ishikawa T, Terai S, Urata Y, et al. Fibroblast growth factor 2 facilitates the differentiation of transplanted bone marrow cells into hepatocytes. Cell Tissue Res. 2006; 323: 221-31
|
|
|
|
|
|
14) Omori K, Terai S, Ishikawa T, et al. Molecular signature associated with plasticity of bone marrow cell under persistent liver damage by self-organizing-map-based gene expression. FEBS Lett. 2004; 578: 10-20
|
|
|
|
|
|
15) Yokoyama Y, Terai S, Ishikawa T, et al. Proteomic analysis of serum marker proteins in recipient mice with liver cirrhosis after bone marrow cell transplantation. Proteomics. 2006; 6: 2564-70
|
|
|
|
|
|
16) Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol Res. 2008; 38(s1The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan): S72-S5
|
|
|
|
|
|
17) Lyra AC, Soares MB, da Silva LF, et al. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol. 2007; 13: 1067-73
|
|
|
|
|
|
18) Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007; 10: 459-66
|
|
|
|
|
|
19) Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol. 2007; 13: 3359-63
|
|
|
|
|
|
20) Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009; 21: 1199-205
|
|
|
|
|